top of page
Supported projects
Yomi Pharma
Exploits the natural properties of the sortilin protein to develop therapeutic solutions targeting EGFR-positive tumours. Their first innovation is a sortilin-derived peptide designed to treat lung adenocarcinoma.
PSCC's entrance
Décembre 2025
Localization
FR - Nouvelle Aquitaine
Modality
Targeted therapy
Development status
Biotech - Lead optimization
Lauréat (s)
bottom of page